Roche Holding AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RHHBY research report →
Range $63 – $63
Price Chart
About the company
Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies.
- CEO
- Thomas Schinecker
- IPO
- 2003
- Employees
- 103,249
- HQ
- Basel, BS, CH
Get TickerSpark's AI analysis on RHHBY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $384.04B
- P/E
- 26.45
- Fwd P/E
- 24.09
- PEG
- 0.89
- P/S
- 4.60
- P/B
- 10.05
- EV/EBITDA
- 14.05
- Div Yield
- 2.41%
- Gross Margin
- 73.32%
- Op Margin
- 31.92%
- Net Margin
- 20.25%
- ROE
- 37.12%
- ROIC
- 20.82%
Latest fiscal year · YoY change
- Revenue
- $63.36B+1.5%
- Gross Profit
- $46.71B+1.3%
- Op Income
- $18.48B
- Net Income
- $12.88B+55.6%
- EPS
- $2.02+55.5%
- OCF Growth
- -15.3%
- FCF Growth
- -10.8%
- Beta
- 0.35
- RSI (14)
- 46
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Roche posted solid half-year 2026 growth with core operating profit rising faster than sales, helped by pharma momentum, diagnostics recovery ex-China, and continued pipeline/regulatory progress.· July 23, 2026
- Core operating profit rose 10% at constant exchange rates, outpacing 6% sales growth and lifting the core operating margin by 1.7 points.
- Core EPS increased 9%, while operating free cash flow rose 21%; management said the tax rate was 17.5% and expects it to be around 20% for the full year, perhaps a little lower.
- Pharma sales grew 6% to CHF 23.6 billion; diagnostics sales grew 3% to CHF 6.7 billion, or 6% excluding China pricing reform.
- Roche highlighted 5 U.S. FDA priority reviews, 2 positive Phase III readouts, and an 80% Phase III success rate year to date.
- Guidance was reiterated: mid-single-digit sales growth, high-single-digit core EPS growth, and higher dividends in Swiss francs.
- Diagnostics said it still expects full-year 2026 margin to be broadly stable versus 14.4% in 2025, despite China pricing reform and U.S. tariffs.
Roche reported half-year 2026 sales growth of 6% at constant exchange rates, with pharma up 6% (to CHF 23.6 billion) and diagnostics up 3% (to CHF 6.7 billion); excluding China, diagnostics grew 6%. Core operating profit rose 10% and core operating margin increased by 1.7 percentage points; core EPS rose 9%, IFRS net income rose 6%, operating free cash flow rose 21%, and free cash flow rose 58% (all at constant exchange rates where stated). Management cited a roughly CHF 200 million flu-season impact on group results, roughly CHF 244 million in loss of exclusivity, about CHF 43 million in diagnostics U.S. tariffs, and said full-year 2026 LOE impact is now expected to be roughly CHF 600 million. Forward guidance was reiterated for mid-single-digit sales growth, high-single-digit core EPS growth, and further dividend increases in Swiss francs; diagnostics expects 2026 margin broadly stable versus 14.4% in 2025.
Thomas Schinecker struck a confident tone, saying Roche had a ‘strong performance’ with ‘significant portfolio progress’ and that growth came from both pharma and diagnostics. He emphasized the breadth of the portfolio, market share gains in brands like Vabysmo, Hemlibra, Tecentriq and Gazyva, and said Roche feels ‘comfortable’ with its momentum into the rest of 2026 and beyond. He also highlighted disciplined business development, saying Roche was not the highest bidder in its deals and is allocating capital carefully.
Alan Hippe focused on the financial bridge from sales to profit, pointing to cost discipline, favorable mix, and centralized SG&A as key drivers of the 10% core operating profit increase. He said other revenue rose by CHF 258 million, cost of sales increased 5%, R&D rose 1%, and SG&A rose 3%, while operating free cash flow rose 21% and net debt increased by CHF 5.9 billion mainly due to dividend payments and taxes/treasury effects. He also noted gross debt was stable at CHF 31.6 billion year-end and CHF 31.8 billion at half year, and that the full-year tax rate should be around 20%, perhaps a little lower.
The visible Q&A began with Citi’s Graham Glyn Parry asking about divarasib: whether the long Phase II PFS could lead to an earlier readout than the trial’s listed October 2028 primary completion date, and whether the asset’s peak-sales opportunity could be above the current 1-2 billion range given the strong data. Teresa Graham replied that Roche would give a broader update at Pharma Day, including on the whole development program. The transcript cuts off before a fuller answer, but management signaled the upcoming investor day would address pipeline and commercial questions in more depth.
The bull case from this call is that Roche is growing profit faster than sales, with margin expansion, strong cash generation, and a reiterated outlook despite currency and China headwinds. The pipeline/regulatory engine also looked active: 5 priority reviews, multiple filings, and several positive late-stage readouts across pharma and diagnostics. Management sounded confident that key products like Vabysmo, Hemlibra, Gazyva, and new diagnostics launches can sustain momentum.
The main risks discussed were China diagnostics pricing reform, U.S. tariffs, foreign exchange pressure, and competitive intensity in several franchises including Alecensa, Ocrevus, Gazyva, and Xolair. Management also flagged a weaker flu season that hurt group results by more than CHF 200 million and said the second half will carry a higher tax rate and continued headwinds from upcoming competitor launches. In pharma, some franchises are expected to peak or slow, including the HER2 franchise peaking in 2026 and Alecensa expected to be flat for the year.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 10.1%
- Shares Outstanding
- 6.37B
- Float Shares
- 646.17M
of shares held by institutions
71 13F filers
Congressional trading
Senate and House stock disclosures for RHHBY, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Sep 11, 26 | Filing → |
| Ritchie TorresHouse · NY15 | Sell | Jul 11, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Apr 9, 25 | Filing → |
| Bruce WestermanHouse · AR04 | Sell | Apr 21, 25 | Filing → |
| Bruce WestermanHouse · AR04 | Buy | Mar 3, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jul 23, 24 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jun 21, 24 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jul 10, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | May 16, 23 | Filing → |
| Dan MeuserHouse · PA09 | Sell | Mar 27, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Buy | Mar 31, 23 | Filing → |
| Dan MeuserHouse · PA09 | Sell | Feb 28, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Feb 27, 23 | Filing → |
| Diana HarshbargerHouse · TN01 | Sell | Jan 25, 23 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Aristotle Capital Management, LLC | 1.49M | ▼ 482.34K |
| Saratoga Research & Investment Management | 1.15M | ▼ 36.10K |
| Boston Common Asset Management, LLC | 350.57K | ▲ 50.42K |
| S&Co Inc | 230.41K | ▲ 100 |
| Altrius Capital Management Inc | 212.88K | ▲ 22.58K |
| Opal Capital LLC | 118.08K | ▲ 118.08K |
| Huntington National Bank | 113.86K | ▼ 3.63K |
| Ar Asset Management Inc | 107.00K | ▼ 300 |
| Rhumbline Advisers | 100.91K | ▲ 2.27K |
| Meritage Portfolio Management | 84.78K | ▲ 84.78K |
| Sterling Capital Management LLC | 58.83K | ▼ 1.46K |
| Kornitzer Capital Management Inc /Ks | 57.27K | ▼ 4.60K |
Held by 25 ETFs
Biggest fund positions in RHHBY by dollar value.
Our RHHBY coverage
Recent articles, reports, and earnings notes.
No research on RHHBY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RHHBY report →